Alaunos Therapeutics Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great to be here. Appreciate everyone, especially the early morning slot. They are real go-getters. Excited to tell you about Velaris today. There we go. I will be making forward-looking statements. Velaris was set up out of Paragon to develop a pipeline of drugs going after pulmonary hypertension and related cardiopulmonary diseases. When you look at PAH, or pulmonary arterial hypertension, significant unmet need, mortality, like survival curves, one mechanism really has risen to the top. That is activin signaling. One drug, sotatercept, or now Winrevair, has launched very well over the past few years. This was Acceleron acquired by Merck, and it has launched incredibly well, which we will get into in a moment. Nothing else has really come behind this as a second-in-class mechanism. What we are doing is we are advancing quickly, something that phenocopies sotatercept, to go quickly into PAH.
We will be in the clinic next year with phase I-B proof of concept data, which is very nice and dose-dependent. It should be quite reified. We are bringing a number of next-gen approaches as well, VLR247 and VLR258, which bear BMP9/10, and we will get into the biology of that in a bit. We are the first company to also be bringing combinations to this space, so PDGFB. We are advancing to the clinic next year. We will look to this as a potentially best-in-class mono, and also the first-in-class combination approach in PAH. Outside of PAH, I think is where the story gets quite interesting as well. We will be looking at heart failure, so specifically HFpEF, where sotatercept just put up very strong, hazard ratio of less than 0.2 data in phase II, and they are now moving to phase III.
We look to be first in class across five or so different pulmonary indications, all which have blockbuster potential, and we will have first mover advantage there. This is data which I think many people might have actually missed, which is within Merck, sotatercept is off to a very strong launch. So $2 billion two years in. I think this is one of the more under-the-radar launches out there, and it is looking to do $8 billion-$10 billion in PAH alone. When we compare PAH on the left to the other indications where sotatercept and activin signaling could be employed, I think this tells a story of how this could be one of the larger classes out there, again, under the radar. PAH, 30,000-50,000 patients, $8 billion peak.
The cardiac indication, pulmonary hypertension of heart failure with preserved ejection fraction, what is called HFpEF for short, about 10 times as many potential patients in that indication. Merck just put out phase II proof of concept data showing a hazard ratio of 0.18, which is kind of unheard of these days in any heart failure study. So they are now moving that into phase III, just the lower dose. We think room to improve on the dose there. In respiratory indications, there has been a number of different PAH drugs with less efficacy that have transitioned from PAH into interstitial lung disease, PH-COPD, IPF, PPF. Nobody has tried formally to take an activin drug into those indications. We look to be the first movers. We will get into some of the anecdotal and clinical evidence out there from doctors that are doing this already, putting out quite compelling data.
This just shows the lung and the heart are connected. Pulmonary vascular remodeling does happen due to imbalanced growth signaling, and this is why outside of just group one, which is pulmonary arterial hypertension, this mechanism also works in group two and group three diseases. Group two being left-sided heart failure, that HFpEF we talked about, and group three being interstitial lung diseases, ILD, IPF, COPD, et cetera. Activin signaling just rebalances the growth, so you make the vessel much more patent and able to deliver blood and therefore transport oxygen. Our lead program, VLR199, as you can see on the left, it rebalances the proliferative and anti-proliferative mechanisms to reopen that blood vessel and allow for oxygen to be carried more effectively. On the right, you can see how we compare to Winrevair or sotatercept in our preclinical studies.
You can see that we very closely pharmacomimetic Winrevair's mechanism of action, giving us confidence to take this drug aggressively forward. Outside of PAH, where we will look to improve upon what sotatercept does in terms of dosing, delivery, and a number of other factors with our clinical strategy in PAH, we are going to move aggressively into HFpEF, where we can be a fast follower. Merck, they relied on their PAH dosing, and we think that there's room to improve as their top dose did not deliver, and only the lower dose is currently being taken forward. It is in phase III, though, very, very impressive results, but we'll look to see if we can optimize dosing further, and then be first in class in PH-ILD and additional opportunities like COPD, IPF, PPF.
These are the sorts of indications, where 20, 30 billion dollar biotechs have recently launched drugs, and we think the efficacy here could be quite profound. What's really nice about PAH is that you can move quite rapidly, and there are precedent data that we can rely on to get very quick proof of concept. You can see here, going from left to right, phase I, II, and III. The phase I, we will run a SAD, and we'll look for a dose-dependent biomarker where we'll look to replicate what sotatercept has done. We'll then do phase IIs in PAH, HFpEF, and the lung diseases, which can then quickly go to registrational studies. Very nice regulatory precedent here, and the unmet need is still incredibly high in these patients. So, plenty of appetite out there globally for these indications and to get these trials enrolling.
This is just that phase I data, which will be really the first data that we put on the board after we get into the clinic next year. Some phase Is, you look to prove that it's safe, and then you move forward into phase II. I think here, there is a very clear dose-dependent biomarker, serum FSH, and we're showing sotatercept's data, or Winrevair on the left. We'll look to replicate this with our phase I data, giving us confidence and informing the doses that we then take into phase II. We'll also look for hemoglobin changes and other biomarker changes closely linked with activin signaling. Following the phase I, our phase II will look to optimize the dose. These can be pretty tight studies, right? Talking 100 to 150 patients, so pretty seamless.
Then we will go into a phase III design, where again, regulatory pathways are quite clear, approval precedent, and six-minute walk duration. Beyond PAH, I think, is where there is significant upside and where you will see us focus a lot of our story, because again, heart failure, roughly 10 times the number of patients. The Merck data was quite impressive, and I think a lot of room to improve for options for patients in this space. Then across lung disease, right? Interstitial lung, COPD, IPF, PPF, these are all ILD is the closest in terms of PAH is 50,000 patients, ILD 60,000-70,000. The others are obviously much larger. So, each a potential blockbuster indication where docs are already using this, and we will get into that data shortly. This is the heart failure data that I mentioned.
You can see the PAH data for sotatercept on the left with a hazard ratio of 0.16. Again, right, these are trials that end up getting paused early because equipoise demands that the drug be approved faster. On the right, you can see the heart failure data of 0.18 that Winrevair delivered just earlier this year. Again, at that lower 0.3 mg per kg dose, the 0.7 actually looked worse. So we think room to potentially improve there. They are advancing into phase III and will look to be a fast follower. A number of PAH drugs have gone from PAH into ILD and pulmonary fibrosis with remarkable success, despite having more limited PAH data. So we are excited to take the most active PAH drug into these diseases and see what we can do. Two examples that I think will just be familiar for investors.
United, of course, with Tyvaso, prostacyclin. It does achieve stat sig in PAH, but is nowhere near as effective as sotatercept. Two positive IPF phase IIIs just read out, following an ILD phase III. They are doing a few billion in these indications. Roivant, of course, took a drug that had been shelved for PAH and reported a few months ago positive phase II data, leading to a pretty nice market reaction, and they are now moving quickly into phase III. We would expect to do something similar. A bit more around kind of the signal that has been seen in these lung diseases. A bit of a complicated slide, but in gray is sotatercept PAH data. You can contrast that with the standard of care, treprostinil, in orange. You can see that on six-minute walk and BNP, you see a very nice improvement for sotatercept versus inhaled prostacyclins.
Then you can see that docs have, of course, noticed this, and they have tried this in their patients in a number of different case reports in group three lung diseases. The first kind of lime green from Patel, then the darker green from Dogar. You can see heretofore unseen changes in six-minute walk duration in group three patients. Really nice improvements in PVR, which would be expected given the mechanism of sotatercept, and very nice changes in BNP as well. So this is not just a hypothesis, but docs are actually doing this given that they have used these patients before, used different PAH drugs in ILD, and seen really nice results. Beyond kind of our lead program and moving aggressively into the group one, two, and three diseases, we are trying a few next-generation approaches as well.
We structured this company so that whatever mechanism that anybody is trying in PAH, we want to be the winner. We built in a number of different call options into the company, because if sotatercept can be improved upon, we want to be the ones to do it. Two distinct approaches that we're taking beyond our lead 199 are VLR247 and VLR258. Here, we've dialed out BMP9 and 10 signaling. It gets a bit complicated, but BMP9 and 10 lead to hemoglobin increases, and they limit the amount of efficacy that can be achieved with sotatercept because they limit the dose. You really want to hit activin A and B hard, but you can only do so much without changing too much hemoglobin and BMP9 and 10. People have tried to go after this and do it.
GSK acquired a company earlier this year, 35Pharma, that is currently in phase II in both PAH and HFpEF, that heart failure indication. That data's coming next year. If that data's positive, then we will be positioned quite well to move forward our VLR258 and VLR247 into the same indications where GSK is playing, potentially able to push the dose without worrying about those side effects. If that does not read out positively, then we will continue forward with 199 as planned. Additionally, there emerging work on PDGFB. This stems from a really impressive dataset that imatinib, which is, of course, GLEEVEC, a cancer drug produced in PAH, where it showed similar efficacy data, almost as profound as sotatercept, with an orthogonal mechanism. Of course, imatinib does carry tox, so close to 30% dropout rate despite that really nice efficacy benefit.
It was not carried forward given the efficacy safety equipoise was not there. However, it's thought to be that PDGFB was the primary driver of that efficacy. Regeneron is currently in phase II with a PDGFB selective antibody. We are coming into the clinic next year with a half-life extended antibody against PDGFB, so we can improve upon their dosing and look to develop this not only as a monotherapy on their heels, but we would be uniquely positioned to combine this with our lead, and we have engineered these to be co-formulatable. So quite excited to see that readout, and if there is safety that does not overlap with SOTA, as well as a modicum of efficacy, even anything incremental, we would look to be first in class combining it in PAH and also consider additional indications. This just shows the mechanisms a bit more.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
1 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
